These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011 [TBL] [Abstract][Full Text] [Related]
6. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. Faust J; Menke J; Kriegsmann J; Kelley VR; Mayet WJ; Galle PR; Schwarting A Arthritis Rheum; 2002 Nov; 46(11):3083-95. PubMed ID: 12428253 [TBL] [Abstract][Full Text] [Related]
7. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044 [TBL] [Abstract][Full Text] [Related]
8. Lupus nephritis reoccurs following transplantation in the lupus prone mouse. Hamar P; Wang M; Godo M; Kokeny G; Rosivall L; Ouyang N; Heemann U Lupus; 2010 Feb; 19(2):175-81. PubMed ID: 19946036 [TBL] [Abstract][Full Text] [Related]
9. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157 [TBL] [Abstract][Full Text] [Related]
10. Attenuation of autoimmune disease in Fas-deficient mice by treatment with a cytotoxic benzodiazepine. Bednarski JJ; Warner RE; Rao T; Leonetti F; Yung R; Richardson BC; Johnson KJ; Ellman JA; Opipari AW; Glick GD Arthritis Rheum; 2003 Mar; 48(3):757-66. PubMed ID: 12632430 [TBL] [Abstract][Full Text] [Related]
11. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. Mannoor K; Matejuk A; Xu Y; Beardall M; Chen C J Immunol; 2012 Apr; 188(8):3628-38. PubMed ID: 22407922 [TBL] [Abstract][Full Text] [Related]
12. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Hasegawa H; Kohno M; Sasaki M; Inoue A; Ito MR; Terada M; Hieshima K; Maruyama H; Miyazaki J; Yoshie O; Nose M; Fujita S Arthritis Rheum; 2003 Sep; 48(9):2555-66. PubMed ID: 13130475 [TBL] [Abstract][Full Text] [Related]
13. IK cytokine ameliorates the progression of lupus nephritis in MRL/lpr mice. Muraoka M; Hasegawa H; Kohno M; Inoue A; Miyazaki T; Terada M; Nose M; Yasukawa M Arthritis Rheum; 2006 Nov; 54(11):3591-600. PubMed ID: 17075801 [TBL] [Abstract][Full Text] [Related]
14. Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice. Goury A; Meghraoui-Kheddar A; Belmokhtar K; Vuiblet V; Ortillon J; Jaisson S; Devy J; Le Naour R; Tabary T; Cohen JH; Schmidt AM; Rieu P; Touré F J Immunol; 2015 Apr; 194(8):3612-22. PubMed ID: 25762779 [TBL] [Abstract][Full Text] [Related]
15. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. Schwarting A; Wada T; Kinoshita K; Tesch G; Kelley VR J Immunol; 1998 Jul; 161(1):494-503. PubMed ID: 9647261 [TBL] [Abstract][Full Text] [Related]
16. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells. Yao L; Chen HP; Ma Q Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470 [TBL] [Abstract][Full Text] [Related]
17. Role of inducible costimulator in the development of lupus in MRL/lpr mice. Tada Y; Koarada S; Tomiyoshi Y; Morito F; Mitamura M; Haruta Y; Ohta A; Nagasawa K Clin Immunol; 2006 Aug; 120(2):179-88. PubMed ID: 16616645 [TBL] [Abstract][Full Text] [Related]
18. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Hou LF; He SJ; Li X; Yang Y; He PL; Zhou Y; Zhu FH; Yang YF; Li Y; Tang W; Zuo JP Arthritis Rheum; 2011 Aug; 63(8):2445-55. PubMed ID: 21484768 [TBL] [Abstract][Full Text] [Related]
19. Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice. Tada Y; Nagasawa K; Ho A; Morito F; Koarada S; Ushiyama O; Suzuki N; Ohta A; Mak TW J Immunol; 1999 Sep; 163(6):3153-9. PubMed ID: 10477582 [TBL] [Abstract][Full Text] [Related]
20. C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice. Wenderfer SE; Ke B; Hollmann TJ; Wetsel RA; Lan HY; Braun MC J Am Soc Nephrol; 2005 Dec; 16(12):3572-82. PubMed ID: 16207826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]